Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Pharmacokinetic Study in Healthy Subjects to Evaluate the Relative Bioavailability of Risankizumab Following Subcutaneous Administration With On-Body Injector

NCT06937619 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06937619
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06937619 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Pharmacokinetic Study in Healthy Subjects to Evaluate the Relative Bioavailability of Risankizumab Following Subcutaneous Administration With On-Body Injector
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Completed
Start date
April 21, 2025
Completion date
November 10, 2025
Enrollment
263 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteer